文献速递免疫规划传染病防控与疫情报告

脑膜炎奈瑟菌X血清群血清杀菌抗体检测方法的验证及其在尼日尔血清流行病学研究中的应用

Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa.
PubMed 文献 · Vaccine · 2022-09-08

研究在尼日尔2012年采集的377份血清样本中评估X血清群自然免疫,并验证X血清群血清杀菌抗体(SBA)检测法;52.3%的参与者存在自然免疫,5-14岁组推定保护滴度(≥8)比例最高(73.9%),<1岁组为0%;该检测法在选择性/特异性、精密度/重现性、线性和稳定性方面验证成功,适用于含X血清群多糖的脑膜炎球菌结合疫苗临床试验。

要点

  • 尼日尔2012年血清样本中52.3%存在X血清群自然免疫。
  • 5-14岁组推定保护滴度(≥8)比例最高(73.9%),<1岁组为0%。
  • X血清群SBA检测法在选择性/特异性、精密度/重现性、线性和稳定性方面验证成功。

核心结论

  • 尼日尔社区中X血清群自然免疫普遍存在(52.3%),X血清群SBA检测法验证成功,适用于含X血清群多糖的脑膜炎球菌结合疫苗临床试验。

研究设计与样本

  • 血清流行病学研究,纳入2012年西非尼日尔采集的血清样本n=377,并验证X血清群血清杀菌抗体(SBA)检测法。

主要发现

  • 自然免疫针对X血清群存在于52.3%的研究参与者中。
  • X血清群推定保护滴度(≥8)在5-14岁组最高(73.9%),在<1岁组最低(0%)。
  • SBA检测法在选择性/特异性、精密度/重现性、线性和稳定性方面验证成功。

关键数值与推荐

  • X血清群推定保护滴度定义为≥8。
  • 5-14岁组73.9%具有推定保护滴度(≥8),<1岁组0%。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Invasive meningococcal disease (IMD) affects approximately 1.2 million people worldwide annually. Prevention of IMD is mostly provided through vaccination; however, no licensed vaccine is currently available to protect against meningococcal serogroup X associated infection. Limited data are available on the natural immunity to Neisseria meningitidis serogroup X within the African sub-Saharan meningitis belt. The objective of the study was to provide an overview of natural immunity to serogroup X within a community in the African meningitis belt prior to the introduction of a pentavalent conjugate vaccine (NmCV-5). Prior to its introduction, a validated assay to assess vaccine efficacy was also required. This study therefore incorporated two objectives: a seroprevalence study to assess natural immunity in serum samples (n = 377) collected from Niger, West Africa in 2012, and the validation of a serogroup X serum bactericidal antibody (SBA) assay. Seroprevalence data obtained found that natural immunity to N. meningitidis serogroup X were present in 52.3% of study participants. The highest putative protective titres (≥8) to serogroup X were seen in age group 5-14 years-old (73.9%) and lowest in ages < 1 year old (0%). The SBA assay was successfully validated for selectivity/specificity, precision/reproducibility, linearity, and stability. This study demonstrated the suitability of the serogroup X SBA assay in clinical trials for future meningococcal conjugate vaccines containing serogroup X polysaccharides.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Katz S, Townsend-Payne K, Louth J, et al. Validation and use of a serum bactericidal antibody assay for Neisseria meningitidis serogroup X in a seroprevalence study in Niger, West Africa. Vaccine. 2022. PMID: 36089429. doi:10.1016/j.vaccine.2022.08.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。